Guizhou Bailing Group Pharmaceutical Co Ltd (002424) — Financial Flexibility Index
Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of CN¥298.34 Million (operating CF CN¥294.76 Million minus capex CN¥3.59 Million) represents 0% of total liabilities (CN¥3.00 Billion). Check Guizhou Bailing Group Pharmaceutical Co (002424) strategic asset index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Guizhou Bailing Group Pharmaceutical Co Ltd Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Guizhou Bailing Group Pharmaceutical Co Ltd across 19 annual periods. See Guizhou Bailing Group Pharmaceutical Co (002424) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
Year-by-year free cash flow to debt coverage for Guizhou Bailing Group Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see market cap of Guizhou Bailing Group Pharmaceutical Co .
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.29x | CN¥873.96 Million | CN¥748.72 Million | CN¥3.02 Billion | ▲ +2129.6% |
| 2024 | 0.01x | CN¥51.04 Million | CN¥9.02 Million | CN¥3.94 Billion | ▼ -78.4% |
| 2023 | 0.06x | CN¥229.89 Million | CN¥125.77 Million | CN¥3.82 Billion | ▼ -69.5% |
| 2022 | 0.20x | CN¥570.60 Million | CN¥502.15 Million | CN¥2.90 Billion | ▼ -33.6% |
| 2021 | 0.30x | CN¥750.65 Million | CN¥324.92 Million | CN¥2.53 Billion | ▲ +187.1% |
| 2020 | 0.10x | CN¥321.80 Million | CN¥231.78 Million | CN¥3.11 Billion | ▼ -48.9% |
| 2019 | 0.20x | CN¥589.32 Million | CN¥467.41 Million | CN¥2.91 Billion | ▲ +1559.9% |
| 2018 | -0.01x | CN¥-28.43 Million | CN¥-157.45 Million | CN¥2.05 Billion | ▼ -108.4% |
| 2017 | 0.17x | CN¥224.57 Million | CN¥79.88 Million | CN¥1.36 Billion | ▼ -69.0% |
| 2016 | 0.53x | CN¥625.95 Million | CN¥466.62 Million | CN¥1.17 Billion | ▲ +16.2% |
| 2015 | 0.46x | CN¥534.27 Million | CN¥413.23 Million | CN¥1.16 Billion | ▲ +13.8% |
| 2014 | 0.40x | CN¥492.32 Million | CN¥395.83 Million | CN¥1.22 Billion | ▲ +137.2% |
| 2013 | 0.17x | CN¥230.50 Million | CN¥141.76 Million | CN¥1.35 Billion | ▲ +2.3% |
| 2012 | 0.17x | CN¥199.68 Million | CN¥19.52 Million | CN¥1.20 Billion | ▼ -54.5% |
| 2011 | 0.37x | CN¥394.98 Million | CN¥201.90 Million | CN¥1.08 Billion | ▲ +223.7% |
| 2010 | -0.30x | CN¥-281.99 Million | CN¥-447.68 Million | CN¥952.49 Million | ▼ -189.6% |
| 2009 | 0.33x | CN¥147.22 Million | CN¥125.31 Million | CN¥445.48 Million | ▲ +485.3% |
| 2008 | -0.09x | CN¥-27.51 Million | CN¥-40.42 Million | CN¥320.72 Million | ▲ +63.2% |
| 2007 | -0.23x | CN¥-73.70 Million | CN¥-79.37 Million | CN¥315.87 Million | — |